Attovia Therapeutics

US · ATTO #3464 by market cap Listed 2026

16.42 -1.08 -6.17%

Live - 5344 symbols - heartbeat 88s ago · 2026-10-08 07:41

Pre-market 16.97 +3.35%

After-hours 16.42 0.00%

Market cap: 749.59M
P/E (TTM): -10.65
P/B: -5.15
EPS: -1.42
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on ATTO?

Anonymous reader poll. Unscientific, not investment advice.

About Attovia Therapeutics

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

CEO: Mr. Tao Fu
Employees: 44
Fiscal year end: 12-31
Website: attovia.com

Company profile

Exchange: US
Symbol: ATTO
Market-cap rank: #3464
Listing date: 2026-08-05
Market cap: 749.59M
Float cap: 279.14M
Shares out: 45.65M
Float shares: 17.00M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 07:41:20 · For reference only, not investment advice and not tailored to your situation.